Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Safe Orthopaedics S.A. (ALSAF.PA)
Eragny-sur-Oise, FR
Operating as a medical technology firm, Safe Orthopaedics SA specializes in the creation and global distribution of sterile implants and disposable surgical tools designed to address spinal fracture conditions. Its innovative product line includes SteriSpine PS, a comprehensive system for managing both spinal fractures and degenerative spine issues. Additionally, they provide SteriSpine VA, a versatile suite encompassing pre-packaged Kyphoplasty and Cement solutions. The portfolio further extends to SteriSpine LC, offering pre-assembled instrumentation for lumbar cages like Cedar and Elm, and SteriSpine CC, which provides similar ready-to-use instruments for cervical cages, exemplified by Walnut. Established in 2010, the company's main operations are based in Éragny-sur-Oise, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +26.98% | +11.11% | +11.11% | -17.53% | -66.67% | -54.29% | -66.67% | -100.00% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-0.9% Q2'24: -5.1% (vs Q2'22)
-
EPS growth Medical - Instruments & Supplies: +16.3%-4,021.8% Q2'24: -4,868.5% (vs Q2'22)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-3,449.4% Q2'24: -46.7% (vs Q2'22)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-4,666.1% Q2'24: +2,668.7% (vs Q2'22)
-
ROIC Medical - Instruments & Supplies: +6.0%-398.3% Q2'24: +564.1% (vs Q2'22)
-
Share dilution Medical - Instruments & Supplies: +0.1%-28.4% ★ Q2'24: -17.6% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-1.01× Q2'24: 0.72× (vs Q2'22)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|
| Revenue |
3.66M
est: 3.82M (-4.3%)
|
4.55M
est: 4.67M (-2.4%)
|
5.86M
est: 5.88M (-0.3%)
|
5.81M
est: 6.40M (-9.2%)
|
7.70M
est.
|
8.60M
est.
|
| EBITDA |
-6.88M
est: -3.78M (-82.2%)
|
-5.20M
est: -18.26M (+71.5%)
|
-5.62M
est: -23.45M (+76.0%)
|
-268.17M
est: -34.43M (-678.9%)
|
-50.62M
est.
|
-8.53M
est.
|
| EBIT |
-7.45M
est: -3.82M (-94.9%)
|
-6.07M
est: -16.92M (+64.1%)
|
-6.61M
est: -5.88M (-12.5%)
|
-271.10M
est: -31.89M (-750.0%)
|
-27.30M
est.
|
-8.60M
est.
|
| Net Income |
-8.31M
est: -3,927.26T (+100.0%)
|
-6.71M
est: -1,413.81T (+100.0%)
|
-6.97M
est: -1,570.90T (+100.0%)
|
-205.44M
est: -34.12M (-502.1%)
|
-34.38M
est.
|
-15.93M
est.
|
| SGA |
7.52M
est: 3.86M (+94.7%)
|
9.27M
est: 4.72M (+96.3%)
|
307.0K
est: 4.46M (-93.1%)
|
262.0K
est: 6.33M (-95.9%)
|
7.61M
est.
|
8.50M
est.
|
| EPS |
-227,853,436.00
est: -2,775,000.00 (-8,110.9%)
|
-92,620.00
est: -1,998,000.00 (+95.4%)
|
-96,154.00
est: -1,110,000.00 (+91.3%)
|
-2,706,764.00
est: -360,000.00 (-651.9%)
|
-210,000.00
est.
|
-180,000.00
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicolas Papillon | Chief Executive Officer | — | male |
| Philippe Laurito | Chief Executive Officer & Director | — | male |
| Rodolphe Cadio | Administrative & Financial Director & Director | — | male |
| Thomas Droulout | Co-Founder & Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALSAF.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
